Though current vaccines show efficacy, work on next-generation iterations against the South Africa variant is under way.
FDA briefing documents show intriguing findings on asymptomatic prevention, though these are based on small numbers.
As assurances that all is well fall on deaf ears, should Glaxosmithkline be thinking more radically?
Merck & Co’s move illustrates how hard it will be for the second wave of Covid-19 vaccine candidates to succeed.
Pivotal data for JNJ-78436735 are imminent, with Novavax and Curevac not far behind.